Literature DB >> 23638746

T-cell tolerance in cancer.

Junmei Wang1, Anupama Sahoo1, Roza Nurieva1.   

Abstract

T cells are the master regulators of adaptive immune responses and maintenance of their tolerance is critical to prevent autoimmunity. However, in the case of carcinogenesis, the tumor microenvironment aids T-cell tolerance, which contributes to uncontrolled tumor growth. Recently, there has been significant progress in understanding the intrinsic extracellular (positive and negative costimulatory molecules on APCs) and intracellular mechanisms (E3 ubiquitin ligases, transcriptional and epigenetic repressors), as well as extrinsic mechanisms (Tregs and tolerogenic dendritic cells) that are required for the implementation and maintenance of T-cell tolerance. Ultimately, understanding and manipulating T-cell tolerance will help to break the tolerance state in cancer.

Entities:  

Mesh:

Year:  2013        PMID: 23638746      PMCID: PMC5103631          DOI: 10.2217/imt.13.33

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  262 in total

1.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

2.  Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers.

Authors:  M S Shin; H S Kim; S H Lee; W S Park; S Y Kim; J Y Park; J H Lee; S K Lee; S N Lee; S S Jung; J Y Han; H Kim; J Y Lee; N J Yoo
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice.

Authors:  W L Perry; C M Hustad; D A Swing; T N O'Sullivan; N A Jenkins; N G Copeland
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.

Authors:  G V Shurin; M R Shurin; S Bykovskaia; J Shogan; M T Lotze; E M Barksdale
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

5.  Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells.

Authors:  Ye Zheng; Steven Z Josefowicz; Arnold Kas; Tin-Tin Chu; Marc A Gavin; Alexander Y Rudensky
Journal:  Nature       Date:  2007-01-21       Impact factor: 49.962

6.  Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells.

Authors:  Gang Wei; Lai Wei; Jinfang Zhu; Chongzhi Zang; Jane Hu-Li; Zhengju Yao; Kairong Cui; Yuka Kanno; Tae-Young Roh; Wendy T Watford; Dustin E Schones; Weiqun Peng; Hong-Wei Sun; William E Paul; John J O'Shea; Keji Zhao
Journal:  Immunity       Date:  2009-01-16       Impact factor: 31.745

7.  Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.

Authors:  Yu-Fei He; Gui-Mei Zhang; Xiao-Hong Wang; Hui Zhang; Ye Yuan; Dong Li; Zuo-Hua Feng
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

8.  Transcriptional regulation of th2 differentiation by inducible costimulator.

Authors:  Roza I Nurieva; Julie Duong; Hiroko Kishikawa; Umberto Dianzani; Jose M Rojo; I cheng Ho; Richard A Flavell; Chen Dong
Journal:  Immunity       Date:  2003-06       Impact factor: 31.745

9.  FoxP3 maintains Treg unresponsiveness by selectively inhibiting the promoter DNA-binding activity of AP-1.

Authors:  Sang-Myeong Lee; Beixue Gao; Deyu Fang
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

10.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.

Authors:  Srinivas Nagaraj; Kapil Gupta; Vladimir Pisarev; Leo Kinarsky; Simon Sherman; Loveleen Kang; Donna L Herber; Jonathan Schneck; Dmitry I Gabrilovich
Journal:  Nat Med       Date:  2007-07-01       Impact factor: 53.440

View more
  21 in total

Review 1.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

2.  Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.

Authors:  Alexandra Francian; Shelby Namen; Madigan Stanley; Kristine Mann; Holly Martinson; Max Kullberg
Journal:  Nanomedicine       Date:  2018-11-09       Impact factor: 5.307

3.  Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity.

Authors:  Máté Manczinger; Balázs Koncz; Gergő Mihály Balogh; Benjamin Tamás Papp; Leó Asztalos; Lajos Kemény; Balázs Papp; Csaba Pál
Journal:  Nat Cancer       Date:  2021-07-08

Review 4.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  Engineering better immunotherapies via RNA interference.

Authors:  Mouldy Sioud
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 6.  Advances and challenges: dendritic cell vaccination strategies for glioblastoma.

Authors:  Teilo H Schaller; John H Sampson
Journal:  Expert Rev Vaccines       Date:  2016-08-10       Impact factor: 5.217

7.  The Goldilocks Window of Personalized Chemotherapy: Getting the Immune Response Just Right.

Authors:  Derek S Park; Mark Robertson-Tessi; Kimberly A Luddy; Philip K Maini; Michael B Bonsall; Robert A Gatenby; Alexander R A Anderson
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

Review 8.  Extracellular Vesicles and Their Current Role in Cancer Immunotherapy.

Authors:  Carla Giacobino; Marta Canta; Cristina Fornaguera; Salvador Borrós; Valentina Cauda
Journal:  Cancers (Basel)       Date:  2021-05-10       Impact factor: 6.639

9.  Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.

Authors:  Masoud Delfi; Rossella Sartorius; Milad Ashrafizadeh; Esmaeel Sharifi; Yapei Zhang; Piergiuseppe De Berardinis; Ali Zarrabi; Rajender S Varma; Franklin R Tay; Bryan Ronain Smith; Pooyan Makvandi
Journal:  Nano Today       Date:  2021-03-11       Impact factor: 18.962

Review 10.  Modulation of antigen-specific T-cells as immune therapy for chronic infectious diseases and cancer.

Authors:  Suling Li; Alistair L J Symonds; Tizong Miao; Ian Sanderson; Ping Wang
Journal:  Front Immunol       Date:  2014-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.